Denmark’s Novo Nordisk said late Friday that the US Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorization for ...

Among significant research news last week, UK drug developer PureTech released positive new Phase IIb data on its ...

San Diego, USA-based Neurocrine Biosciences today announced the launch of its Crenessity (crinecerfont) in the USA.

Epitopea partners with Genevant Sciences to develop RNA-based cancer immunotherapies targeting proprietary tumor antigens.

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

Zealand Pharma faces a setback as the FDA issues a complete response letter for glepaglutide, requiring a new Phase III trial ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

Swiss pharma giant Novartis (NOVN: VX) is to shut two sites belonging to its MorphoSys unit. The facilities in Munich, ...

Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, ...

The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in ...